Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28499572 | 0.87 | AKR1C4 (0.43) | ALDH1A1GSTP1GSTM2 | |
| SCHEMBL28499573 | 0.87 | AKR1C4 (0.43) | ALDH1A1GSTP1GSTM2 | |
| SCHEMBL5276860 | 0.85 | ALDH1A1 (0.50) | ALDH1A1RAB9AGAANPC1MEN1 | |
| SCHEMBL5276866 | 0.85 | ALDH1A1 (0.50) | ALDH1A1RAB9AGAANPC1MEN1 | |
| SCHEMBL9375784 | 0.81 | ALDH1A1 (0.54) | ALDH1A1RAB9AGAANPC1SMN1; SMN2 | |
| SCHEMBL9375780 | 0.81 | ALDH1A1 (0.54) | ALDH1A1RAB9AGAANPC1SMN1; SMN2 | |
| SCHEMBL14454666 | 0.81 | ALDH1A1 (0.54) | ALDH1A1RAB9AGAANPC1SMN1; SMN2 | |
| SCHEMBL14933701 | 0.80 | MAPK1 (0.49) | ALDH1A1RAB9AGAANPC1SMN1; SMN2 | |
| SCHEMBL6703265 | 0.79 | ALDH1A1 (0.51) | ALDH1A1RAB9AGAANPC1SMN1; SMN2 | |
| SCHEMBL4432206 | 0.79 | ALDH1A1 (0.51) | ALDH1A1RAB9AGAANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572209-A4 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO INC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1572209-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | Merck & Co., Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6908921-B2 | Quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004054584-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO., INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | SGMS2 4332/4885ALDH1A1 3743/4885RAB9A 1991/4885 |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | BDKRB1, BDKRB2, LTB4R2 | SGMS2 4567/4885ALDH1A1 3321/4885RAB9A 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.